Recombinant Human Thrombopoietin Treatment Promotes Hematopoiesis Recovery in Patients with Severe Aplastic Anemia Receiving Immunosuppressive Therapy

Table 1

Patients’ characteristics.

	With rhTPO	Without rhTPO	value
Patients number	40	48
Median age (year, range)	36 (16–66)	32 (16–68)	0.74
Gender, male/female	18/22	27/21	0.39
Severity of disease			0.51
VSAA	27	28
SAA	13	20
Neutrophil counts, ×10^9/L (median, range)	0.15 (0–1.31)	0.16 (0–1.47)	0.46
Platelet counts, ×10^9/L (median, range)	9 (0–28)	10 (0–34)	0.75
Reticulocyte counts, ×10^9/L (median, range)	18 (0.3–43)	14 (0.4–50)	0.62
Lymphocyte counts, ×10^9/L (median, range)	1.48 (0.41–4.17)	1.52 (0.39–3.99)	0.87
Interval from diagnosis to ATG (median, range), days	19 (1–416)	21 (1–839)	0.58